JNJ

223.32

-1.06%↓

UNH

367.27

+1.2%↑

TMO

472.38

+1.51%↑

ISRG

449.68

+0.06%↑

ABT

86.58

-1.04%↓

JNJ

223.32

-1.06%↓

UNH

367.27

+1.2%↑

TMO

472.38

+1.51%↑

ISRG

449.68

+0.06%↑

ABT

86.58

-1.04%↓

JNJ

223.32

-1.06%↓

UNH

367.27

+1.2%↑

TMO

472.38

+1.51%↑

ISRG

449.68

+0.06%↑

ABT

86.58

-1.04%↓

JNJ

223.32

-1.06%↓

UNH

367.27

+1.2%↑

TMO

472.38

+1.51%↑

ISRG

449.68

+0.06%↑

ABT

86.58

-1.04%↓

JNJ

223.32

-1.06%↓

UNH

367.27

+1.2%↑

TMO

472.38

+1.51%↑

ISRG

449.68

+0.06%↑

ABT

86.58

-1.04%↓

Home・Elenco Azioni・Becton Dickinson and Co

Becton Dickinson and Co

Aperta

SettoreSettore sanitario

144.72 -0.17

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

144.04

Massimo

146.25

Metriche Chiave
By Trading Economics
Entrata	-1.3B 382M
Vendite	-639M 5.3B
P/E Media del settore	24.546 67.147
EPS	2.91
Rendimento da dividendi	2.74
Margine di Profitto	7.273
Dipendenti	70,000
EBITDA	-86M 1.2B

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+23.42% upside

Dividendi
By Dow Jones
Rendimento da dividendi Media del settore	2.74% 2.36%
Utili prossimi	7 mag 2026
Prossima data del Dividendo	30 giu 2026
Prossima data del' Ex Dividendo	9 giu 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-15B 43B
Apertura precedente	144.89
Chiusura precedente	144.72

Notizie sul Sentiment di mercato

By Acuity

31%

69%

121 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

167 / 206.99 Supporto e resistenza

Becton Dickinson and Co Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 ago 2025, 11:19 UTC

Utili

Becton Dickinson Boosts Outlook as 3Q Results Beat Estimates

14 lug 2025, 14:26 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal -- 2nd Update

14 lug 2025, 11:08 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal -- Update

14 lug 2025, 10:37 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal

7 ago 2025, 10:32 UTC

Utili

Becton Dickinson Expects to Complete Remaining $250M of $1B Share-Buyback Commitment by End FY25 >BDX

7 ago 2025, 10:31 UTC

Utili

Becton Dickinson Backs FY25 View of Rev $21.8B-$21.9B >BDX

7 ago 2025, 10:31 UTC

Utili

Becton Dickinson Had Seen FY25 Adjusted EPS $14.06-$14.34 >BDX

7 ago 2025, 10:30 UTC

Utili

Becton Dickinson Raises FY25 View To Adj EPS $14.30-Adj EPS $14.45 >BDX

7 ago 2025, 10:30 UTC

Utili

Becton Dickinson 3Q Adj EPS $3.68 >BDX

7 ago 2025, 10:30 UTC

Utili

Becton Dickinson 3Q Net $574M >BDX

7 ago 2025, 10:30 UTC

Utili

Becton Dickinson 3Q Rev $5.51B >BDX

7 ago 2025, 10:30 UTC

Utili

Becton Dickinson 3Q EPS $2.00 >BDX

15 lug 2025, 18:32 UTC

Acquisizioni, Fusioni, Takeovers

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15 lug 2025, 18:31 UTC

Acquisizioni, Fusioni, Takeovers

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

14 lug 2025, 16:12 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

14 lug 2025, 15:06 UTC

Acquisizioni, Fusioni, Takeovers

Waters Stock Is Falling on Deal to Combine With Becton Dickinson Unit -- Barrons.com

14 lug 2025, 14:11 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5B Deal -- 2nd Update

14 lug 2025, 10:53 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal -- Update

14 lug 2025, 10:22 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal

14 lug 2025, 10:22 UTC

Acquisizioni, Fusioni, Takeovers

Waters To Assume About $4 Billion Incremental Debt >WAT BDX

14 lug 2025, 10:22 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson to Get $4 Billion Cash Distribution Prior to Closing >WAT BDX

14 lug 2025, 10:21 UTC

Acquisizioni, Fusioni, Takeovers

Waters Holders to Own 60.8% of Combined Company, Becton Dickinson Holders to Own 39.2% >WAT BDX

14 lug 2025, 10:20 UTC

Acquisizioni, Fusioni, Takeovers

Waters, Becton Dickinson: Combined Company to Have About $9 Billion Revenue, $3.3 Billion Adjusted Ebitda >WAT

14 lug 2025, 10:19 UTC

Acquisizioni, Fusioni, Takeovers

Correct: Waters, Becton Dickinson See About $290 Million Revenue Synergies by Year Five >WAT BDX

14 lug 2025, 10:19 UTC

Acquisizioni, Fusioni, Takeovers

Waters, Becton Dickinson See About $345 Million Annualized Ebitda Synergies by 2030 >WAT BDX

14 lug 2025, 10:18 UTC

Acquisizioni, Fusioni, Takeovers

Waters, Becton Dickinson See About $290 Revenue Cost Synergies by Year Five >WAT BDX

14 lug 2025, 10:18 UTC

Acquisizioni, Fusioni, Takeovers

Waters, Becton Dickinson See About $200 Million Cost Synergies by Year Three >WAT BDX

14 lug 2025, 10:17 UTC

Acquisizioni, Fusioni, Takeovers

Waters: Becton Dickinson Deal Doubles Total Addressable Market to About $40 Billion >WAT

14 lug 2025, 10:16 UTC

Acquisizioni, Fusioni, Takeovers

Waters, Becton Dickinson Deal Structured as Reverse Morris Trust >WAT BDX

14 lug 2025, 10:16 UTC

Acquisizioni, Fusioni, Takeovers

Waters, Becton Dickinson Deal Valued at About $17.5 Billion >WAT BDX

Confronto tra pari

Modifica del prezzo

Becton Dickinson and Co Previsione

Obiettivo di Prezzo

By TipRanks

23.42% in crescita

Previsioni per 12 mesi

Media 180.58 USD 23.42%

Alto 221 USD

Basso 157 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Becton Dickinson and Co - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Becton Dickinson and Co - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

167 / 206.99Supporto e resistenza

Bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

121 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.